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Introduction
Autosomal recessive primary microcephaly is a neurodevelop-
mental disorder characterized by reduced brain size and mental 
retardation in humans (Thornton and Woods, 2009). At least 
eight different loci are known to be responsible for this disease, 
and MCPH1 is one of the seven responsible genes that have 
been identified so far. Its gene product, MCPH1 (also known as 
microcephalin or BRIT1), is an 835–amino acid protein that 
contains three BRCA1 C-terminal (BRCT) domains (Jackson   
et al., 2002): one (BRCT1) is at the N terminus, whereas the 
other two (BRCT2 and BRCT3) are tandemly arranged at the   
C terminus (Fig. 1 A). Although the three BRCT domains and 
their vicinities are reasonably conserved, the sequences com-
prising the large central region are highly variable even among 
vertebrates, implicating that MCPH1 is a rapidly evolving pro-
tein (Fig. S1; Ponting and Jackson, 2005).
The cellular function of MCPH1 and its relationship to the 
etiology of microcephaly are not fully understood. In fact, a   
series of recent studies have been uncovering multiple faces of 
MCPH1 functions, which are as diverse as DNA damage re-
sponse (Xu et al., 2004; Wood et al., 2007; Jeffers et al., 2008), 
cell  cycle  regulation  (Alderton  et  al.,  2006;  Tibelius  et  al., 
2009), transcriptional regulation (Yang et al., 2008), and cen-
trosome regulation (Rai et al., 2008). Among them, perhaps one 
of the best-characterized examples may be -H2AX–dependent 
recruitment  of  MCPH1  to  the  sites  of  DNA  double-strand 
breaks  through  its  BRCT2/3  domains  (Wood  et  al.,  2007;   
Jeffers et al., 2008). It remains to be fully established, however, 
whether  MCPH1  might  act  upstream  or  downstream  of  the 
checkpoint  kinase  Chk1  (Alderton  et  al.,  2006;  Tibelius   
et al., 2009).
Another line of recent studies has started to shed light on 
a  distinct,  less-appreciated  function  of  MCPH1.  Cells  from 
MCPH1 patients were found to display premature chromosome 
condensation (PCC) in G2 phase of the cell cycle, implicating that 
MCPH1 might participate in the regulation of chromosome con-
densation (Trimborn et al., 2004). Central to chromosome con-
densation in vertebrate cells are two multisubunit complexes, 
M
utations  in  human  MCPH1  (hMCPH1)  cause 
primary microcephaly, which is characterized 
by a marked reduction of brain size. Interest-
ingly, hMCPH1 mutant patient cells display unique cellular 
phenotypes, including premature chromosome conden-
sation  (PCC),  in  G2  phase.  To  test  whether  hMCPH1 
might directly participate in the regulation of chromo-
some condensation and, if so, how, we developed a cell-
free assay using Xenopus laevis egg extracts. Our results 
demonstrate that an N-terminal domain of hMCPH1 spe-
cifically inhibits the action of condensin II by competing 
for its chromosomal binding sites in vitro. This simple and 
powerful assay allows us to dissect mutations causing pri-
mary microcephaly in vivo and evolutionary substitutions 
among different species. A complementation assay using 
patient cells revealed that, whereas the N-terminal do-
main of hMCPH1 is sufficient to rescue the PCC pheno-
type, its central domain plays an auxiliary role in shaping 
metaphase chromosomes by physically interacting with 
condensin II. Thus, hMCPH1 acts as a composite modula-
tor of condensin II to regulate chromosome condensation 
and shaping.
MCPH1 regulates chromosome condensation and 









4 and Tatsuya Hirano
1
1Chromosome Dynamics Laboratory, RIKEN Advanced Science Institute, Wako, Saitama 351-0198, Japan
2Institute of Human Genetics, University Wuerzburg, 97074 Wuerzburg, Germany
3Institute of Human Genetics and 
4Institute for Medical Genetics, Charité - Universitätsmedizin Berlin, 13353 Berlin, Germany
©  2011  Yamashita  et  al.  This  article  is  distributed  under  the  terms  of  an  Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after the pub-
lication date (see http://www.rupress.org/terms). After six months it is available under a 
Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, 























YJCB • VOLUME 194 • NUMBER 6 • 2011   842
prevalent scenario that the apparent condensation defects ob-
served in MCPH1-deficient cells are an indirect consequence of 
perturbed cell cycle progression.
In the current study, we have developed a cell-free assay 
using Xenopus laevis egg extracts for studying the action of 
MCPH1 in vitro. Our results provide a convincing set of evi-
dence that an N-terminal domain of human MCPH1 (hMCPH1) 
specifically inhibits the action of condensin II under a meta-
phase-arrested condition, being independent of cell cycle pro-
gression. The cell-free assay is demonstrated to be extremely 
powerful  in  analyzing  microcephaly-causing  mutations  in   
humans and dissecting amino acid substitutions among differ-
ent species. Moreover, a complementation assay using patient 
namely,  condensin  I  and  II  (Swedlow  and  Hirano,  2003;   
Hirano, 2005). The two complexes share a pair of structural 
maintenance of chromosomes (SMC) proteins as their core sub-
units and possess different sets of non-SMC regulatory subunits 
(Ono et al., 2003). Depletion of specific subunits of condensin II, 
but not those of condensin I, from MCPH1 patient cells rescued 
the PCC phenotype, raising the possibility that PCC might be 
caused  by  untimely  activation  of  condensin  II  in  G2  phase 
(Trimborn et al., 2006). However, direct evidence for inhibition 
of condensin II by MCPH1 is lacking. Moreover, MCPH1 is 
known to function as a component of the network that down-
regulates Cdk1 in response to DNA damage (Alderton et al., 2006; 
Tibelius et al., 2009), leaving the alternative and currently 
Figure 1.  hMCPH1 inhibits chromosomal binding of condensin II in Xenopus egg extracts. (A) hMCPH1 possesses three BRCT domains (blue boxes). Also 
shown are two point mutations (T27R and W75R) that cause primary microcephaly in MCPH1 patients. (B) A reticulocyte lysate containing no hMCPH1 
(mock) or FLAG-tagged hMCPH1 was mixed with 10 vol metaphase egg extracts and incubated for 30 min. Sperm chromatin was then added and incu-
bated for another 120 min. Chromosome fractions were isolated and analyzed by immunoblotting with the antibodies indicated. Aliquots of the extracts 
were saved before chromosome isolation and analyzed in parallel. No sperm was added in lanes 1 and 6. (C) Metaphase chromosomes were assembled 
as described in B, fixed, and stained with DAPI, anti–XCAP-H2 (XH2), and anti–XCAP-G (XG). Close-ups of chromosomal regions indicated by the white 
rectangles in c, g, k, and o are shown in c, g, k, and o, respectively. Bar, 5 µm. (D) Sperm chromatin was incubated with Xenopus egg extracts for 
120 min to assemble metaphase chromosomes. 0.1 vol reticulocyte lysates containing no hMCPH1 (mock) or FLAG-tagged hMCPH1 was then added 
and incubated for another 60 min. Chromosome fractions were isolated and analyzed as described in B. (E) Metaphase chromosomes were assembled 
as described in D and analyzed as in C. Bar, 1 µm. The dotted lines indicate where intervening lanes were removed for presentation purposes. cond, 
condensin; topoII, topoisomerase II.843 Regulation of condensin II by MCPH1 • Yamashita et al.
forms of hMCPH1 produced chromosomes that were indistin-
guishable  from  those  assembled  in  the  mock-treated  extract 
(Fig. 1 C, i–p).
We then tested whether hMCPH1 might have an ability   
to strip condensin II from chromosomes that had already been   
assembled in the extracts. To this end, metaphase chromosomes 
were assembled in a control extract, and hMCPH1 was added 
and incubated for another 60 min. Immunoblotting analysis of 
chromosome fractions revealed a significant reduction of the 
level of condensin II but not of condensin I (Fig. 1 D). As judged 
by  morphological  analysis,  again,  hMCPH1-treated  chromo-
somes displayed a zigzag and fragile appearance (Fig. 1 E). 
Taking these results together, we conclude that exogenously 
added hMCPH1 blocks the action of condensin II present in the 
Xenopus egg extracts in a highly specific manner.
An N-terminal domain of hMCPH1 is 
sufficient to specifically inhibit condensin II 
in the cell-free assay
Next, we asked which domains of hMCPH1 might be responsi-
ble for the activity to inhibit condensin II observed in the 
cell-free assay. Selected examples of deletion constructs of 
hMCPH1 tested are shown in Fig. 2 A. In short, we found that 
an N-terminal fragment (amino acids 1–195) containing the first 
BRCT domain (BRCT1) is required and sufficient to inhibit 
loading of condensin II onto chromosomes (Fig. 2 B, lanes 8 
and 9). This N-terminal fragment itself bound to chromosomes, 
but it does so only weakly when compared with a C-terminal 
fragment  (amino  acids  638–835)  containing  the  second  and 
third BRCT domains (Fig. 2 B, lane 10). Introduction of the 
T27R mutation into the N-terminal domain (amino acids 1–195) 
not only abolished its condensin II inhibitory activity (Fig. 2,   
C  and  D)  but  also  weakened  its  own  chromosome-binding   
activity (Fig. 2 C, lane 6). None of the shorter N-terminal   
constructs tested (amino acids 1–95, 1–138, 1–162, and 1–183) 
inhibited condensin II loading in this assay.
A recent study had reported that okadaic acid, a potent in-
hibitor  of  PP2A  (protein  phosphatase  2A),  inhibits  chromo-
somal loading of condensin II in Xenopus egg extracts and in 
human cells (Takemoto et al., 2009). Therefore, we wished to 
compare the impacts of hMCPH1 and okadaic acid in parallel in 
our cell-free assay. We found that okadaic acid blocked loading 
of condensin II, XCAP-D (KIF4a), and aurora B but not of con-
densin I (Fig. 2 E, lanes 11 and 12) as had been reported by 
Takemoto et al. (2009). In contrast, hMCPH1 hardly affected 
loading of XCAP-D and aurora B (Fig. 2 E, lanes 8 and 9), indi-
cating that hMCPH1’s ability to inhibit chromosomal loading 
of condensin II in Xenopus egg extracts is far more specific than 
okadaic acid.
The N-terminal domain of hMCPH1 
competes for chromosome binding of 
condensin II in Xenopus egg extracts
To understand the mechanism by which hMCPH1 inhibits the 
action of condensin II, we wished to test the possibility that the 
N-terminal  domain  of  hMCPH1  might  compete  for  binding 
sites of condensin II on chromosomes. Consistent with this idea, 
cells, combined with a protein–protein interaction assay, re-
veals that the central domain of hMCPH1, in collaboration with 
its N-terminal domain, contributes to proper shaping of meta-
phase chromosomes. Our results suggest that hMCPH1 func-
tions as a composite modulator of condensin II and fine tunes 
the processes of chromosome condensation and shaping.
Results
hMCPH1 inhibits chromosomal binding of 
condensin II in Xenopus egg extracts
To dissect the molecular action of hMCPH1, we sought to de-
velop a cell-free assay by using extracts prepared from unfertil-
ized Xenopus eggs. The use of these egg extracts has two big 
advantages. First, the cell cycle of the unfertilized eggs is natu-
rally arrested at metaphase of meiosis II, at which the activity of 
cyclin B–Cdk1 is kept high (Morgan, 2007). Second, the dy-
namics and function of many chromosomal proteins, including 
condensin I and II, have been characterized extensively in these 
extracts (e.g., Hirano et al., 1997; Ono et al., 2003). These prop-
erties allow us to study the specific role of hMCPH1 in conden-
sin regulation, if any, without being disturbed by other parameters, 
such as cell cycle progression.
We started with a very simple experiment. Full-length 
hMCPH1 was produced in a reticulocyte lysate and preincu-
bated with a metaphase extract for 30 min. Sperm chromatin 
was added into the mixture, and after incubation for another 
120 min, chromosome fractions were isolated and analyzed by 
immunoblotting. Strikingly, we found that exogenously added 
hMCPH1  effectively  inhibited  loading  of  condensin  II  onto 
chromosomes. The effect of hMCPH1 was highly specific to 
condensin II: loading of condensin I and topoisomerase II was 
hardly affected in the same reaction (Fig. 1 B, lanes 7 and 8). 
We then tested whether two point mutations that had been iden-
tified in MCPH1 patients (T27R [Trimborn et al., 2005] and 
W75R [Gavvovidis et al., 2010]) might affect the activity of 
hMCPH1 to inhibit condensin II in this cell-free assay. Remark-
ably, again, both of the mutant proteins barely blocked loading 
of condensin II (Fig. 1 B, lanes 9 and 10), suggesting that this 
cell-free assay could indeed recapitulate an aspect of the physi-
ological functions of hMCPH1.
The biochemical data were fully supported by morpho-
logical analysis. In this experiment, metaphase chromosomes 
were assembled in the presence or absence of hMCPH1, fixed, 
and stained simultaneously with antibodies against condensin I– 
and condensin II–specific subunits (XCAP-G and -H2, re-
spectively). In a mock-treated extract, both condensin I and II 
were readily detectable along the entire length of chromatids 
(Fig. 1 C, a–d) as had been reported previously (Ono et al., 
2003).  In  an  hMCPH1-treated  extract,  however,  the  signal   
for condensin II was lost almost completely, whereas the signal   
for condensin I was unaffected (Fig. 1 C, e–h). We also noticed   
that the axes of chromosomes assembled in the presence of   
hMCPH1 were structurally distorted (Fig. 1 C, g); this zigzag 
morphology was reminiscent of that observed in chromosomes 
assembled in an extract depleted of condensin II (Ono et al., 
2003). As expected, extracts supplemented with the two mutant JCB • VOLUME 194 • NUMBER 6 • 2011   844
Figure 2.  An N-terminal domain of hMCPH1 is sufficient to specifically inhibit chromosomal loading of condensin II in Xenopus egg extracts. (A) Deletion 
constructs of hMCPH1 used in this paper. (B) Full-length hMCPH1 and three different deletion constructs were subjected to the cell-free assay. Chromosome 
fractions and aliquots of the extracts were analyzed by immunoblotting. (C) The same experiment as in B was repeated using the wild-type and mutant 845 Regulation of condensin II by MCPH1 • Yamashita et al.
absence (Fig. 4 C, rows e–h) of endogenous xMCPH1. Simi-
lar results were obtained when the N-terminal domains of   
hMCPH1, mMCPH1, and xMCPH1 were used. In the experi-
ment shown in Fig. 4 D, the dose of the N-terminal domains of 
MCPH1 added into metaphase extracts was titrated down start-
ing from the standard dose. The N-terminal domain of hMCPH1 
displayed a dose-dependent inhibition of condensin II loading 
(Fig. 4 D, lanes 15–18), and substantial inhibition was detect-
able with as low as 25% of the standard dose (Fig. 4 D, lane 16). 
In contrast, a very low level of inhibition was observed even 
with the highest dose of the mouse or Xenopus counterpart 
(Fig. 4 D, lane 22 or lane 26). Although the observation that 
xMCPH1 has a poor activity to inhibit condensin II in the cell-
free assay was somewhat puzzling, it provides a reasonable   
explanation for why depletion of endogenous xMCPH1 from 
the extract had little impact on the behavior of condensin II 
(Fig. 4, A and B).
mMCPH1 can be “humanized” by specific 
amino acid substitutions
To substantiate the findings described in the previous section, 
we sought to identify the determinants that would differenti-
ate the activities between hMCPH1 and mMCPH1. Because 
the N-terminal domains of hMCPH1 and mMCPH1 were 
relatively divergent in their last quarters, each domain was 
divided into two subdomains, A (A
h, amino acids 1–145 in 
hMCPH1; A
m, amino acids 1–151 in mMCPH1) and B (B
h, 
amino acids 146–195 in hMCPH1; B
m, amino acids 152–194 
in mMCPH1), and a chimera protein, referred to as A
mB
h, was 
created (Fig. 5 A and Fig. S1). We found that A
mB
h bound to 
chromosomes  slightly  better  than  the  authentic  mouse  se-
quence (A
mB
m) but failed to acquire an appreciable level of 
activity to inhibit condensin II loading (Fig. 5 B, lane 16). Be-
cause the simple substitution of the subdomain B was not 
enough to confer the hMCPH1-like activity on mMCPH1, we 
took a brute force mutagenesis approach by focusing on non-
conserved residues in the subdomain A. A list of substituted 
residues (singly or in combinations) is shown in Fig. S3 A. In 
short, we found that mMCPH1 acquired an activity compara-
ble with that of hMCPH1 when two mouse to human substitu-
tions, T72R and E142K, were combined with the subdomain B 
substitution (Fig. 5 B, compare lanes 12 and 13). A double 
substitution alone (T72R-E142K) displayed little, if any, ef-
fect (Fig. 5 B, lane 17), indicating that successful conversion 
of the mouse sequence into one with a humanlike activity re-
quires the combination of all three substitutions. Conversely, 
when two human to mouse substitutions were introduced into 
the corresponding residues of hMCPH1 (i.e., R66T-K136E), 
the activity associated with the human protein was greatly   
reduced (Fig. 5 C). Thus, the cell-free assay successfully   
the T27R mutant not only poorly inhibited condensin II but also 
poorly associated with chromosomes as judged by immunoblot-
ting of chromosomal factions (Fig. 2 C). In experiments shown 
in Fig. 3, we attempted double immunofluorescent labeling of 
condensin II and the N-terminal domain of hMCPH1 (a GFP-
tagged version) on chromosomes. As expected, GFP alone or 
the T27R mutant of GFP-hMCPH1 (amino acids 1–195) pro-
duced only a background level of its own signals on chromo-
somes and did not affect loading of condensin II (Fig. 3 A, a–d 
and  m–p).  On  the  other  hand,  GFP-hMCPH1  (amino  acids   
1–195) associated with chromosomes and inhibited loading of 
condensin II in a dose-dependent manner (Fig. 3 A, e–h and i–l). 
Remarkably, we noticed that condensin II and GFP-hMCPH1 
(amino acids 1–195) apparently distributed along chromosomes 
in a mutually exclusive manner (Fig. 3 A, i–l). Under the same 
condition, we found virtually no sign for displacement of con-
densin I by GFP-hMCPH1 (amino acids 1–195) exogenously 
added into the extract (Fig. 3 B). These results suggest that the 
N-terminal domain of hMCPH1 inhibits loading of condensin II 
by competing for its binding sites on chromosomes.
Characterization of Xenopus MCPH1 
(xMCPH1) and mouse MCPH1 (mMCPH1) 
in the cell-free assay
The specific inhibition of condensin II by exogenously added 
hMCPH1 in the cell-free assay raises the question of whether 
Xenopus egg extracts might contain endogenous MCPH1. To 
explore this possibility, we prepared specific antibodies against 
recombinant fragments of xMCPH1 and found that the extracts 
indeed contained an appreciable level of endogenous xMCPH1, 
which was estimated to be comparable with the standard dose 
of hMCPH1 added exogenously (Fig. S2). We reasoned that, if 
xMCPH1 also had an activity to inhibit condensin II, depletion 
of endogenous xMCPH1 from an extract might cause hyper-
activation and overloading of condensin II in the cell-free assay.   
It was found, however, that the presence or absence of endoge-
nous xMCPH1 made little, if any, difference in the morphology 
of chromosomes or the level of condensin II loaded on them 
(Fig. 4, A and B).
MCPH1 is a rapidly evolving protein and is implicated in 
the expansion of brain size during vertebrate evolution (Ponting 
and Jackson, 2005). It would therefore be of considerable inter-
est if MCPH1 proteins from different vertebrate species were sub-
jected to a comparative study in this particular cell-free assay. 
To this end, we added the same dose of full-length MCPH1 
from human, mouse, and Xenopus into a control extract and an 
extract depleted of endogenous xMCPH1 (Fig. S2). Intriguingly, 
we found that, compared with hMCPH1, mMCPH1 or xMCPH1 
displayed a much weaker activity to inhibit chromosomal loading 
of condensin II either in the presence (Fig. 4 C, rows a–d) or   
(T27R) forms of the N-terminal domain (amino acids 1–195). (D) Metaphase chromosomes were assembled in an extract supplemented with the wild-
type and mutant (T27R) forms of the N-terminal domain (amino acids 1–195) as described in B, fixed, and stained with DAPI, anti–XCAP-H2 (XH2), and 
anti–XCAP-G (XG). Close-ups of chromosomal regions indicated by the white rectangles in c, g, and k are shown in c, g, and k, respectively. Bar, 5 µm.   
(E) Metaphase egg extracts were mixed with 0.1 vol reticulocyte lysates containing FLAG-hMCPH1 (amino acids 1–835 [full length] or 1–195) or treated with 
1 or 4 µM okadaic acid. Sperm chromatin was added and incubated for 120 min to assemble metaphase chromosomes. Chromosome fractions were then 
isolated and analyzed as described in B. The dotted lines indicate where intervening lanes were removed for presentation purposes. cond, condensin.
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work by Wood et al. (2008), we found that a central domain 
of hMCPH1 (amino acids 381–435) was primarily responsible 
for the condensin II–hMCPH1 interaction (Fig. S4, C and D) 
and further identified a pair of point mutations (Y412A and 
F416A) in the central domain that disrupts this interaction 
(Fig. S4 E). Consistently, full-length hMCPH1 added into 
Xenopus extracts interacted with endogenous condensin II, 
and such an interaction was largely abolished when the F416A 
mutation  was  introduced  into  hMCPH1  (Fig.  6  A).  The 
F416A mutant protein, however, was found to retain a full 
activity to inhibit condensin II loading in the cell-free assay 
(Fig. 6 B). This observation was surprising at first glance, yet 
allowed us to identify a subset of specific amino acid substitu-
tions  that  contributes  to  the  functional  difference  between 
hMCPH1 and mMCPH1.
Robust interaction with condensin II 
through its central domain is not required 
for hMCPH1’s inhibitory activity in the  
cell-free assay
We then tested for physical interactions between hMCPH1 
and condensin II. In HeLa cell nuclear extract, endogenous 
hMCPH1  and  human  condensin  II  specifically  interacted 
with each other (Fig. S4, A and B). By extending the previous 
Figure 3.  The N-terminal domain of hMCPH1 competes for chromosome binding of condensin II in Xenopus egg extracts. (A) A reticulocyte lysate contain-
ing GFP or GFP-hMCPH1 (amino acids 1–195; wild type and T27R) was mixed with 10 vol metaphase egg extracts and incubated for 30 min. Sperm 
chromatin was then added and incubated for another 120 min. Metaphase chromosomes assembled were fixed and stained with DAPI (a, e, i, and m), 
anti–XCAP-H2 (XH2; b, f, j, and n), and anti-GFP (GFP; c, g, k, and o). To reduce the dose of GFP-hMCPH1 (amino acids 1–195) to 50% (i–l), the reticu-
locyte lysate containing the wild-type protein was diluted twofold with a mock lysate before being mixed with the egg extracts. Close-ups of chromosomal 
regions indicated by the white rectangles in i–l are shown in i–l. (B) Metaphase chromosomes assembled in the presence of GFP-hMCPH1 (amino acids 
1–195; wild type) as described in A were fixed and stained with DAPI (a), anti–XCAP-G (XG; b), and anti-GFP (GFP; c). Close-ups of chromosomal regions 
indicated by the white rectangles in a–d are shown in a–d. Bars, 5 µm. cond, condensin.847 Regulation of condensin II by MCPH1 • Yamashita et al.
identify which subunits of condensin II might be responsible for 
interactions with hMCPH1. To test this, the three regulatory 
subunits of human condensin II (CAP-D3, -G2, and -H2) were 
individually translated in vitro, unmixed or mixed in all possible 
pairwise  combinations,  and  processed  for  subunit–subunit 
interaction assays with full-length or truncated versions of 
it was consistent with our result that the N-terminal region 
(amino acids 1–195) of hMCPH1 is sufficient for condensin II 
inhibition (Fig. 2).
We then sought the possibility that the N-terminal domain 
of hMCPH1 might possess a minor condensin II–interacting 
activity independently of its central region. We also wished to 
Figure 4.  Characterization of xMCPH1 and mMCPH1 in the cell-free assay. (A) Sperm chromatin was added to metaphase egg extracts that had been 
depleted with control IgG (mock; lanes 1 and 3) or anti-xMCPH1 (xMCPH1; lanes 2 and 4). After incubation for 120 min, chromosomes were isolated, 
and their associated polypeptides (lanes 3 and 4) and aliquots of the extracts (lanes 1 and 2) were analyzed by immunoblotting using the antibodies indi-
cated. (B) Metaphase chromosomes were assembled in the mock-depleted (mock; a–d) or xMCPH1-depleted (xMCPH1; e–h) extracts, fixed, and double 
stained with anti–XCAP-H2 (XH2) and anti–XCAP-G (XG). Bulk chromosomal DNA was counterstained with DAPI. (C) A reticulocyte lysate containing no 
hMCPH1 () or FLAG-tagged full-length MCPH1 from human, mouse, and Xenopus was mixed with 10 vol metaphase egg extracts that had been depleted 
with control IgG (mock; rows a–d) or anti-xMCPH1 (xMCPH1; rows e–h) and incubated for 30 min. Sperm chromatin was then added and incubated 
for another 120 min. The resulting metaphase chromosomes were analyzed as in B. (D) Increasing concentrations of the N-terminal (N-ter.) domains of 
human, mouse, and Xenopus MCPH1 were mixed with metaphase egg extracts (lanes 1–13) and tested for their ability to inhibit chromosomal loading of 
condensin (cond) II. The relative concentrations of MCPH1 added were 1:8 (lanes 2, 6, and 10), 1:4 (lanes 3, 7, and 11), 1:2 (lanes 4, 8, and 12), and 
1 (lanes 5, 9, and 13); the highest concentration roughly corresponded to the standard one used in other experiments. Sperm chromatin was incubated 
with these extracts, and chromosome-bound fractions (lanes 14–26) were isolated and analyzed by immunoblotting. Bars, 5 µm.JCB • VOLUME 194 • NUMBER 6 • 2011   848
Complementation assay reveals  
a contribution of the central  
domain of hMCPH1 to shaping  
metaphase chromosomes
Finally, we wished to understand to what extent the information 
obtained from the cell-free assay might be relevant to the in vivo 
function of hMCPH1. To this end, we set up a complementation 
assay in which various constructs of hMCPH1 were expressed in 
MCPH1 patient cells bearing a homozygous truncating muta-
tion by means of a lentivirus vector. In the first set of experiments, 
GFP-tagged versions of full-length hMCPH1 were introduced 
into the patient cells, and their expression was confirmed by   
hMCPH1 (Fig. 6 C). In short, we found that the central domain 
(amino acids 381–435) of hMCPH1 coprecipitated predomi-
nantly with CAP-G2, whereas the N-terminal domain (amino 
acids 1–195) did primarily with the D3 subunit (Fig. S4 F).   
Together with our previous data showing no direct interaction 
between CAP-G2 and -D3 subunits (Onn et al., 2007), we con-
clude that two separate domains of hMCPH1 are capable of in-
teracting with different HEAT subunits of condensin II (Fig. 6 C, 
cartoon). It should be noted, however, that the interaction be-
tween  the  N-terminal  domain  of  hMCPH1  and  CAP-D3  is 
rather cryptic and not readily detectable in the context of the 
condensin II holocomplex (Fig. 6 A and Fig. S4 D).
Figure 5.  mMCPH1 can be converted into a humanlike, competent form by specific amino acid substitutions. (A) Schematic representation of the constructs 
used in B. The N-terminal domain of hMCPH1 was divided into two subdomains, A
h (amino acids 1–145) and B
h (amino acids 146–195), and the cor-
responding domain of mMCPH1 was divided into A
m (amino acids 1–151) and B
m (amino acids 152–194), accordingly. A chimera form (A
mB
h) was cre-
ated, and single or double point mutations (T72R and E142K) were further introduced in an attempt to confer a humanlike activity on the mouse sequence 
(mouse to human). (B) Mouse to human conversion. The constructs shown in A were subjected to the cell-free assay. (C) Human to mouse conversion. Two 
point mutations (R66T and K136E) were introduced singly or doubly into the human sequence, and the resulting constructs were subjected to the cell-free 
assay. cond, condensin; N-ter., N-terminal; XG, XCAP-G; XH2, XCAP-H2.849 Regulation of condensin II by MCPH1 • Yamashita et al.
To study whether hMCPH1 might impact the morphology 
of metaphase chromosomes, chromosome spreads were pre-
pared and stained with an antibody against Smc2, a core subunit 
shared by both condensin I and II. In MCPH1 patient cells 
(either mock treated or transduced with GFP alone), most of 
metaphase chromosomes displayed an abnormal morphology 
with very short and thick chromatids. When these so-called 
“dumpy” chromosomes were stained with anti-Smc2, chromatid 
axes with a characteristic wavy appearance could be visualized   
(Fig. 7 C, a and graph, bars 1 and 2). When the patient cells ex-
pressing GFP-hMCPH1 were analyzed, the dumpy phenotype 
immunoblotting against total cell lysates (Fig. 7 A). The fre-
quency of prophaselike cells (PLCs) in each cell population was 
scored (Fig. 7 B; also see Materials and methods). We found that 
wild-type hMCPH1 rescued the PCC phenotype very efficiently 
(Fig. 7 B and see Fig. S5 [A and B] for representative images). 
On the other hand, an hMCPH1 construct with the mild allele 
T27R failed to fully restore the defective phenotype (Trimborn   
et al., 2005). Notably, a construct with the F416A mutation dis-
played a full activity to restore the PCC phenotype, suggesting that 
the interaction with condensin II mediated through the central do-
main of hMCPH1 is dispensable for rescuing the PCC phenotype.
Figure  6.  hMCPH1  physically  interacts  with  con-
densin II through its N-terminal and central domains.  
(A) A reticulocyte lysate containing no hMCPH1 (mock) 
or FLAG-tagged hMCPH1 was mixed with 10 vol meta-
phase egg extracts and incubated for 60 min. Anti-FLAG 
beads were then added into the mixtures, and bound 
fractions and aliquots of the mixtures were analyzed 
by immunoblotting. Different levels of contrast adjust-
ment were performed between the input and immuno-
precipitation (IP) blots. The FLAG data are derived from 
a different membrane than the condensin (cond) II data. 
Nonspecific bands that cross reacted with anti–XCAP-
G2 (XG2) are indicated by the asterisk. (B) Sperm chro-
matin was incubated with the mixtures as described in A 
for 120 min, and chromosome fractions were isolated 
and  analyzed  by  immunoblotting.  (C)  FLAG-tagged 
non-SMC subunits of human condensin II (CAP-D3, -G2, 
and -H2) were translated individually in reticulocyte ly-
sates and mixed in different combinations as indicated. 
Three different versions of GFP-tagged hMCPH1 were 
produced  in  different  reactions,  incubated  with  the 
aforementioned  mixtures,  and  subjected  to  immuno-
precipitation with anti-GFP. The immunoprecipitates and 
5% of input fractions were analyzed by immunoblotting 
with anti-FLAG and anti-GFP. FLAG data are derived 
from a different membrane than the GFP data for the top 
and middle datasets. The asterisks indicate nonspecific 
bands. The major binding partners of the central (cen; 
amino  acids  381–435)  and  N-terminal  (N;  amino   
acids 1–195) domains of hMCPH1 are CAP-G2 and -D3, 
respectively (cartoon). The dotted lines indicate where 
intervening lanes were removed for presentation pur-
poses. XH2, XCAP-H2.JCB • VOLUME 194 • NUMBER 6 • 2011   850
Figure 7.  The N-terminal domain of hMCPH1 is sufficient to rescue the PCC phenotype, whereas its central domain is additionally required for shaping 
metaphase chromosomes in patient cells. (A) MCPH1 patient cells were transduced with GFP-tagged full-length hMCPH1 by means of a lentivirus expression 
system. Mock-transduced cells and cells transduced with GFP alone were used as negative controls. Lysates were prepared from these cells and analyzed 
by immunoblotting with the indicated antibodies. (B) The cells described in A were fixed and stained with DAPI. The percentages of prophaselike cells 
(PLCs) in such populations were scored and plotted (*, P < 0.05; ***, P < 0.001 between each pair; PLCs were scored from three independently prepared 
coverslips [n = 3]). Representative examples of nuclear morphology in cells expressing GFP alone or GFP-hMCPH1 (wild type) are shown in Fig. S5 (A and B). 
By definition, the PLCs include not only G2 cells displaying PCC but also early G1 cells displaying delayed chromosome decondensation (Trimborn et al., 
2006). In the current study, we follow this definition for the analysis of PLCs. However, when the percentages of the PLCs in patient cells were lowered to 
the basal level, we describe it as a “PCC rescue” for simplicity. (C) Chromosome spreads were prepared from the cells described in A and stained with 
DAPI and anti-Smc2. The morphology of chromosomes from 20 spreads was classified into three categories, and each sample was scored accordingly.   
(a) “Dumpy” is a category of short chromosomes with wavy axes that are commonly observed in the MCPH1 patient cells. (c) “Straight” is a category 
of long chromosomes with straight axes that are routinely observed in nonpatient cells. (b) “Intermediate” is a category belonging between dumpy and 
straight. Representative images of each category (stained with anti-Smc2) are shown at the top. Representative data from two independent experiments are 
shown. Bar, 5 µm. (D) MCPH1 patient cells were transduced with GFP alone or the GFP-tagged N-terminal domain of hMCPH1. Lysates were prepared from 
these cells and analyzed by immunoblotting as described in A. (E and F) The percentages of PLCs and the morphology of chromosome spreads were scored 
as described in B and C, respectively. For F, representative data from two independent experiments are shown. (G) A postulated change of condensin 
(Cond) II activity is shown by the red line. To prevent PCC in G2 phase, the N-terminal (N) domain of MCPH1 is sufficient. To properly shape metaphase 
chromosomes, both the N-terminal and central (cen) domains are required. Error bars indicate means ± SD.851 Regulation of condensin II by MCPH1 • Yamashita et al.
Then, mechanistically, how might the N-terminal domain 
of hMCPH1 inhibit the action of condensin II? Although many, if 
not all, BRCT domains are known to function as phosphopeptide-
binding motifs (Glover et al., 2004), hMCPH1’s BRCT1 does 
not possess key residues involved in such molecular recogni-
tion. It is therefore unlikely that hMCPH1’s action on con-
densin II involves phosphopeptide binding. Instead, our results 
show that the N-terminal domain of hMCPH1 associates with 
chromosomes and effectively competes for binding sites of con-
densin II in the cell-free assay. In fact, analyses of the T27R 
mutation causing primary microcephaly in humans (Figs. 2 and 3) 
and  evolutionary  substitutions  among  different  organisms 
(Figs. 4 and 5) further confirm and establish that the chromo-
some-binding activity of this domain is tightly coupled to its 
condensin II inhibitory activity. The potential mechanism by 
which condensin II is targeted to chromosomes remains to be 
determined (Hirano, 2005). We anticipate that hMCPH1 will be 
an excellent tool for addressing this important problem in the 
future. Moreover, it should be added that the weak interaction 
observed between the N-terminal domain of hMCPH1 and the 
CAP-D3 subunit (Fig. 6) might also contribute, at least in part, 
to specific inhibition of condensin II.
hMCPH1 regulates chromosome 
condensation and shaping in human cells
The morphology of metaphase chromosomes is determined 
by a delicate balance of actions between condensin I and con-
densin II (Ono et al., 2003; Shintomi and Hirano, 2011). It is 
reasonable to speculate that the loss of function of hMCPH1 
would disturb such a balance, thereby leading to the forma-
tion of dumpy chromosomes. Our current data suggest that the 
central domain of hMCPH1 contributes to proper shaping of 
metaphase chromosomes by using its ability to associate with 
condensin II (Fig. 7 G). Although it remains to be determined 
how the central domain might collaborate with the N-terminal 
domain to execute this function, one possibility would be that 
combined actions of the two domains help increase the mobil-
ity of condensin II and thereby promote its proper distribution 
along chromosomes. Thus, rather than being a simple inhibi-
tor, MCPH1 is likely to act as a composite modulator of conden-
sin II that fine tunes its function and distribution, presumably 
throughout the cell cycle. In fact, condensin II’s action is not 
limited to mitosis and contributes to a wide range of inter-
phase chromosome functions (Gosling et al., 2007; Hartl et al., 
2008). Condensin II therefore must have a basal level of ac-
tivity to fulfill these nonmitotic functions within the inter-
phase nucleus. We infer that MCPH1 keeps this basal activity 
of condensin II below a certain threshold during G2 phase, 
thereby preventing PCC from occurring before mitotic entry 
(Fig. 7 G). This idea would explain why a low level of MCPH1 
activity (e.g., T27R) is able to partially suppress PCC during 
G2 phase in human cells but barely inhibits a fully activated 
form of condensin II in metaphase egg extracts. Similarly, al-
though mMCPH1 possesses a low level of activity as judged 
by the cell-free assay (see the following section), it seems suf-
ficient to suppress PCC in mouse cells (Wood et al., 2008; 
Trimborn et al., 2010).
was barely observed; 80% of chromosomes in the sample dis-
played a more typical morphology with long, thin, and straight 
chromatids (Fig. 7 C, c and graph, bar 3). As expected, expres-
sion of the T27R mutant protein failed to rescue the dumpy 
phenotype effectively (Fig. 7 C, bar 4). In contrast, somewhat 
unexpected was the observation that the F416A protein rescued 
the phenotype only partially (Fig. 7 C, bar 5).
We then asked whether expression of the N-terminal 
domain (amino acids 1–195) of hMCPH1 was sufficient to rescue 
the PCC and/or dumpy phenotypes (Fig. 7 D). The wild-type 
N-terminal  domain  efficiently  rescued  the  PCC  phenotype, 
whereas the corresponding domain containing the T27R muta-
tion displayed a partial rescue (Fig. 7 E), an observation similar 
to that made with the full-length proteins (Fig. 7 B). Two addi-
tional constructs (amino acids 196–835 and 638–835) lacking 
the  N-terminal  domain  failed  to  rescue  the  PCC  phenotype   
(Fig. S5, C–E). We noticed, however, that expression of the   
N-terminal domain alone was not sufficient to fully rescue 
the dumpy phenotype in patient cells (Fig. 7 F). Collectively, 
the  current  results  suggest  that  the  N-terminal  domain  of 
hMCPH1 is sufficient to rescue the PCC phenotype but that 
both the N-terminal and central domains are required for prop-
erly shaping metaphase chromosomes.
Discussion
In the current paper, we have established a powerful combina-
tion of the cell-free and complementation assays to study the 
functional and physical interactions between MCPH1 and con-
densin II. In particular, the newly developed cell-free assay pro-
vides us with a simple and semiquantitative method for studying 
the action of MCPH1 in vitro, thereby opening a new avenue in 
the research field of primary microcephaly.
hMCPH1 specifically inhibits condensin II  
in Xenopus egg extracts
Previous work showed that depletion of condensin II from 
MCPH1 patient cells relieved chromosome condensation de-
fects, leading to the proposal that MCPH1 might act as a nega-
tive regulator of condensin II (Trimborn et al., 2006). It has 
remained unclear, however, whether MCPH1 directly inhibits 
condensin II or indirectly down-regulates its activity by per-
turbing its upstream cell cycle regulators (e.g., Alderton et al., 
2006; Tibelius et al., 2009). The cell-free assay established in 
the current study utilizes a Xenopus egg extract whose cell cycle 
state is stably maintained at metaphase (Morgan, 2007). Our 
current results therefore provide the most compelling evi-
dence available, so far, that hMCPH1 has the ability to inhibit 
the action of condensin II independently of the parameter of 
cell cycle progression. We also show that the N-terminal do-
main (amino acids 1–195) of hMCPH1 is required and suffi-
cient for this inhibitory activity. Importantly, the mutations 
identified in MCPH1 patients (T27R and W75R) compromise 
the ability of hMCPH1 to inhibit condensin II in the cell-free 
assay, arguing that loss of this inhibitory activity (hence, mis-
regulation of condensin II) might directly be relevant to the 
etiology of MCPH1 microcephaly.JCB • VOLUME 194 • NUMBER 6 • 2011   852
stresses (Hirano, 2005; Chin and Yeong, 2010). Perturbation of 
such putative checkpoint functions could specifically affect the 
unique mode of cell divisions during neurogenesis (Thornton 
and Woods, 2009). In any case, to fully understand the physiologi-
cal functions of MCPH1, we need to learn more about its mo-
lecular functions. The current study paves the way toward this 
goal by demonstrating that MCPH1 functions as a specific mod-
ulator of condensin II, thereby establishing a potential link between 
chromosome condensation and brain development in vertebrates.
Materials and methods
Antibodies
Rabbit antisera were raised against a C-terminal recombinant fragment 
(amino acids 378–835) of hMCPH1. We also prepared rabbit polyclonal 
antisera against two different recombinant fragments (amino acids 118–
328 and 458–791) of Xenopus mcph1. All recombinant proteins were   
expressed from the pRSETA vector (Invitrogen) in Escherichia coli as hexa-
histidine (His6) fusions. Soluble proteins were purified on a Ni-Sepharose 6 
Fast Flow (GE Healthcare), whereas insoluble proteins were purified by 
electroelution after SDS-PAGE. For affinity purification of rabbit antibodies 
(Hirano et al., 1997), a rabbit antiserum was passed over a column pack-
ing Affi-Gel (Bio-Rad Laboratories) coupled to recombinant protein three 
times, and the column was washed initially with TBS (20 mM Tris-HCl, 
pH 7.5, and 0.15 M NaCl) and then with TBS containing 0.5 M NaCl and 
0.2% Triton X-100 and again with TBS. The IgG bound to the column was 
then eluted with 0.2 M glycine-HCl, pH 2.0, containing 0.15 M NaCl. 
Peak fractions were pooled, dialyzed against TBS, and then used as puri-
fied antibodies. Other antibodies used in this study were described previ-
ously (Hirano et al., 1997; Losada et al., 2002; Ono et al., 2003). The 
following antibodies were obtained from commercial sources: anti–-tubulin 
(clone  DM1A;  Sigma-Aldrich),  anti-GFP  (rabbit  polyclonal,  ab6556; 
Abcam), anti-GFP (mouse monoclonal, ab38689; Abcam), and anti-FLAG 
M2 (F3165; Sigma-Aldrich).
Plasmid construction and mutagenesis
For expression of GFP-tagged hMCPH1 (or its truncated forms) in 293T 
cells, the pEGFP-C2 vector (Takara Bio Inc.) was used. For in vitro transcrip-
tion/translation reactions, the pTnT vector (Promega), a pTnT derivative 
with a 3×FLAG sequence (Shintomi and Hirano, 2009), and a pTnT deriva-
tive with a GFP-encoding sequence were used. For lentiviral expression, a 
vector (GFP.IN.pCL1THPC) was used that expresses GFP and the neomycin-
resistant gene under the control of the spleen focus-forming virus U3 pro-
moter. Point mutations were introduced with a site-directed mutagenesis kit 
(QuikChange XL; Agilent Technologies).
The cell-free assay using Xenopus egg extracts
Metaphase egg extracts and demembranated sperm chromatin were pre-
pared as described previously (Hirano et al., 1997). In brief, low-speed 
supernatants were prepared by crushing the unfertilized eggs of Xenopus 
in XBE2 buffer (10 mM K-Hepes, pH 7.7, 0.1 M KCl, 2 mM MgCl2, 0.1 mM 
CaCl2, 5 mM EGTA, and 50 mM sucrose) and further fractionated by cen-
trifugation at 50,000 rpm at 4°C for 120 min in a rotor (TLS55; Beckman 
Coulter) in an ultracentrifuge (Optima TLX; Beckman Coulter). The soluble 
fractions were collected and centrifuged again at 50,000 rpm for 30 min. 
The resulting supernatants (i.e., high-speed supernatants) were used as meta-
phase egg extracts. Sperm chromatin was prepared in SMH buffer (20 mM 
K-Hepes, pH 7.5, 2 mM MgCl2, and 250 mM sucrose) containing 0.4% 
BSA and 30% glycerol. For biochemical analysis, metaphase extracts were 
diluted  twofold  with  XBE8  (XBE2  containing  8  mM  rather  than  2  mM 
MgCl2), and sperm chromatin was added at a final concentration of 4,000 
nuclei/µl (Ono et al., 2003). After incubating at 22°C for 120 min, the 
mixtures were overlaid on a 30% sucrose cushion made in XBE2 and spun 
at 13,000 rpm for 15 min at 4°C in a rotor (TMS-21; TOMY) in a microfuge 
(MX-305; TOMY). After removing soluble fractions, chromosome fractions 
recovered in the pellets were analyzed by immunoblotting. For morphologi-
cal analysis, metaphase extracts were mixed with sperm chromatin at a final 
concentration of 1,000 nuclei/µl. After incubating at 22°C for 120 min, the 
assembly mixtures were fixed with 10 vol of 2% formaldehyde in XBE2 
containing 0.1% Triton X-100 for 10 min at room temperature and centri-
fuged at 7,000 rpm in a swinging-bucket rotor (JS13.1; Beckman Coulter) 
in a centrifuge (Avanti HP-25; Beckman Coulter) for 15 min onto coverslips 
Evolutionary implications
MCPH1 is a rapidly evolving protein (Ponting and Jackson, 
2005). The current study is the first to compare the activities of 
MCPH1 from different vertebrates in a single functional assay 
in vitro. Unexpectedly, we find that mMCPH1 or xMCPH1 dis-
plays a substantially lower level of activities compared with 
hMCPH1. Assessing MCPH1’s ability to inhibit condensin II in 
the cell-free assay is technically straightforward and highly re-
producible, having allowed us to quickly identify a specific 
combination of amino acid substitutions that confer the func-
tional difference between hMCPH1 and mMCPH1. Notably, 
one of the key residues identified (R66 in humans) is absolutely 
invariable among primates, whereas another key residue (K136 
in humans) and subdomain B are more variable even among pri-
mates (Fig. S3 B). Apart from these residues, it was noticed that 
only two residues (M96 and S101) are unique to humans in the 
N-terminal domain of MCPH1. To test the possibility that these 
two human-specific residues might confer the high inhibitory 
activity on hMCPH1, we substituted them with the nonhuman-
type residues. It was found, however, that the resulting mutant 
protein (M96T-S101P) retained the same level of inhibitory ac-
tivity as wild-type hMCPH1 in the cell-free assay (Fig. S3 C).
To what extent might the functional difference between 
hMCPH1  and  mMCPH1  observed  in  the  cell-free  assay  be 
physiologically significant? We are fully aware that one needs 
to be very cautious about discussing functional evolution of 
MCPH1 on the basis of limited information currently available 
and that any hypotheses must vigorously be validated in vivo. 
Nevertheless, it seems reasonable to argue that the cell-free   
assay described here will be instrumental in addressing the evo-
lutionary aspect of this class of proteins in future studies.
Beyond chromosome condensation: might 
condensin II function in brain development?
The etiology of MCPH1 primary microcephaly is not fully   
understood (Thornton and Woods, 2009). Remarkably, we find 
that the mutations identified in MCPH1 patients (T27R and 
W75R) compromise the ability of hMCPH1 to inhibit conden-
sin II in our cell-free assay. These results suggest that loss of 
this inhibitory activity might indeed be relevant to the etiology 
of MCPH1 microcephaly. Then, how might misregulation of 
condensin II potentially be linked to microcephaly in humans? 
We consider two possibilities, both of which are admittedly 
highly speculative at present. First, it is possible that MCPH1 
mutations cause up-regulation of condensin II, which in turn 
perturbs the program of gene expression supporting normal de-
velopment of the brain. Consistent with this notion, accumulat-
ing lines of evidence suggest that condensin II may play a direct 
role in gene regulation (Hartl et al., 2008) and/or cell differenti-
ation (Gosling et al., 2007). Second, condensin II might func-
tion,  along  with  MCPH1,  as  a  component  of  the  signaling 
network that responds to DNA damage (Alderton et al., 2006; 
Tibelius et al., 2009). In this sense, it is interesting to note that 
condensin II has been hypothesized to be a potential target of 
the surveillance system (the so-called antephase checkpoint) 
that helps reverse an early phase of chromosome condensation 
and prevents mitotic entry in response to a range of cellular 853 Regulation of condensin II by MCPH1 • Yamashita et al.
KCl at 37°C for 30 min, and centrifuged onto poly-l-lysine–coated cover-
slips at 1,000 rpm for 10 min in a cytocentrifuge (Cytospin 2; Thermo 
Fisher Scientific). The chromosome spreads were fixed and permeabi-
lized as described in the previous section, blocked with 3% BSA in PBS, 
and incubated for 2 h with an anti-Smc2 antibody at a final concentra-
tion of 2 µg/ml. Alexa Fluor 568–labeled goat anti–rabbit IgG (Invitro-
gen) was used as a secondary antibody at a 1:500 dilution. The samples 
were counterstained with DAPI and mounted on slides with Vectashield. 
The images of 20 chromosome spreads of each sample were obtained 
with the microscope (BX51) as described in The cell-free assay using 
Xenopus egg extracts section, and the phenotypes were categorized as 
shown in Fig. 7 (C and F).
Extract preparation and immunoprecipitation of human cells
For siRNA-mediated depletion of hMCPH1, HeLa cells were transfected 
twice with 100 nM siRNA duplexes (Thermo Fisher Scientific) by means of 
Oligofectamine (Invitrogen) at 24 and 48 h after seeding. Control cells 
were transfected with a transfection mixture containing no siRNAs. The se-
quences of the sense strand of the siRNA duplexes were as follows: sihM-
CPH1  #1,  5-AGGAAGUUGGAAGGAUCCAdTdT-3;  and  sihMCPH1 
#2, 5-CUCUCUGUGUGAAGCACCUdTdT-3 (in which dT stands for de-
oxythymidine). For immunoblotting analysis of total lysates from HeLa cells, 
2 × 10
5 cells were suspended in 50 µl of SDS sample buffer and heat de-
natured for 5 min. A 5-µl aliquot was resolved by SDS-PAGE and analyzed 
by immunoblotting. HeLa nuclear extracts were prepared in buffer B (20 mM 
K-Hepes, pH 8.0, 100 mM KCl, 2 mM MgCl2, 0.2 mM EDTA, 20% glyc-
erol, 1 mM -mercaptoethanol, and 0.5 mM PMSF) as described previ-
ously (Losada et al., 2000). In brief, asynchronously growing HeLa cells 
were hypotonically treated, homogenized, and centrifuged. The pellet con-
taining nuclei was extracted with buffer B containing 300 mM KCl, homog-
enized, sonicated, and centrifuged at 16,500 rpm at 4°C for 30 min in a 
rotor (SS34; Sorval). The supernatant was dialyzed against buffer B and 
clarified by another centrifugation at 16,500 rpm for 20 min, and then, the 
resulting supernatant was used as a HeLa nuclear extract. For immunopre-
cipitation, 20 µl of the extracts was incubated with 1 µg affinity-purified 
antibody at 4°C for 60 min with occasional mixing. Immunoprecipitates 
were recovered on 10 µl rProtein A Sepharose beads, washed three times 
with buffer B supplemented 0.1% NP-40 and twice with buffer B, and ana-
lyzed by immunoblotting. For immunoprecipitation from total cell extracts, 
293T cells transiently expressing GFP-hMCPH1 were resuspended in a   
lysis buffer (20 mM K-Hepes, pH 7.7, 100 mM KCl, 0.1% NP-40, 2 mM 
MgCl2, 10% glycerol, 40 mM -glycerophosphate, 0.5 mM PMSF, and 
10 µg/ml each of leupeptin, chymostatin, and pepstatin A) at a concentra-
tion of 10
7 cells/ml, incubated at 4°C for 30 min, sonicated briefly, and 
centrifuged at 13,000 rpm in a microfuge for 10 min. 1 µg affinity-purified 
antibody was added to 200 µl extracts and incubated on ice for 60 min. 
Immunoprecipitates were recovered on 10 µl rProtein A Sepharose beads, 
washed several times with wash buffer (20 mM K-Hepes, pH 7.7, 100 mM 
KCl, 2 mM MgCl2, and 10% glycerol), and analyzed by immunoblotting.
Immunodepletion of Xenopus egg extracts
10 µg of the affinity-purified antibodies against xMCPH1 was mixed with 
25 µl rProtein A Sepharose beads and incubated for 60 min at 4°C. The 
antibody-coupled beads were washed and equilibrated with XBE2. 50 µl 
of the egg extracts was incubated with 25 µl antibody beads on ice for 
60 min with occasional mixing. After incubation, the supernatants were re-
covered by brief spin and used as depleted extracts. For mock depletion, 
the same amount of control rabbit IgG (Sigma-Aldrich) was used.
Online supplemental material
Fig. S1 shows primary structures of vertebrate MCPH1. Fig. S2 shows that 
the amounts of exogenously added MCPH1 proteins are comparable with 
that of endogenous xMCPH1. Fig. S3 shows our attempts to identify amino 
acid residues that might confer a high level of condensin II inhibitory activ-
ity on hMCPH1. Fig. S4 shows additional data for physical interactions 
between hMCPH1 and condensin II. Fig. S5 shows that the N-terminal do-
main of hMCPH1 is necessary and sufficient to rescue the PCC phenotype 
in patient cells. Online supplemental material is available at http://www 
.jcb.org/cgi/content/full/jcb.201106141/DC1.
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through a 30% glycerol cushion made in XBE2. Chromosomes spun on the 
coverslips were processed for immunofluorescence as described previously 
(Ono et al., 2003). In brief, the coverslips were blocked with 1% BSA in 
TBS containing 0.1% Triton X-100 and then incubated with the primary 
antibodies. Alexa Fluor 568– and Alexa Fluor 488–labeled IgG (Invitrogen) 
were used as secondary antibodies. The samples were counterstained with 
DAPI, mounted on slides with Vectashield (Vector Laboratories), and observed 
under a microscope (BX51; Olympus) with an UPlanSApo 100×/1.40 NA 
oil objective lens (Olympus). All grayscale images were obtained by a 
cooled charge-coupled device camera (DP30; Olympus) with DP Controller 
software (Olympus), pseudocolored, and merged using Photoshop (Adobe). 
To produce recombinant proteins in reticulocyte lysates, the TNT Quick 
Coupled Transcription/Translation System (Promega) was used. A typical 
reaction mixture (50 µl) containing 1 µg plasmid DNA was supplemented 
with 20 µM methionine and incubated at 30°C for 90 min.
Immunoprecipitation
For in vitro subunit–subunit interaction assays, reticulocyte lysates contain-
ing recombinant proteins were diluted 10-fold with a dilution buffer (20 mM 
K-Hepes, pH 7.7, 100 mM KCl, 2.5 mM MgCl2, 0.1% Tween 20, and 
0.5 mg/ml BSA), rotated at 4°C for 60 min, and spun at 13,000 rpm in a 
microfuge at 4°C for 10 min. The supernatants were incubated with 1 µg 
affinity-purified antibody on ice for 60 min. Immunoprecipitates were recov-
ered on 10 µl rProtein A Sepharose beads (GE Healthcare), washed three 
times with the dilution buffer and once with the dilution buffer without Tween 
20 and BSA, and analyzed by immunoblotting. For the experiment shown 
in Fig. 6 A, egg extracts were supplemented with 0.1 vol reticulocyte ly-
sates and incubated at 22°C for 60 min. The mixtures were incubated with 
5 µl FLAG M2 beads (Sigma-Aldrich) at 4°C for 60 min with occasional 
mixing. The beads were washed three times with KMH (20 mM K-Hepes, 
pH 7.7, 100 mM KCl, and 2 mM MgCl2) containing 0.1% Triton X-100, 
twice with KMH, and subjected to SDS-PAGE.
Transduction of MCPH1 patient cells with recombinant lentiviruses
SV40-transformed fibroblasts were derived from a patient with a homozy-
gous MCPH1 truncating mutation (p.Thr143AsnfsX5; Trimborn et al., 2006). 
The lentiviral system used in this study was designed to express GFP-tagged 
hMCPH1 under the control of the spleen focus-forming virus U3 promoter. 
All  recombinant  lentiviruses  were  produced  by  transient  transfection  of 
293FT cells as follows. Subconfluent 293FT cells were cotransfected with 
GFP.IN.pCL1THPC containing an hMCPH1 insert, pCAG-HIVgp, and 
pCMV-VSV-G-RSV-Rev (Miyoshi et al., 1998; the latter two plasmids were 
provided  by  H.  Miyoshi,  RIKEN  BioResource  Center,  Tsukuba,  Ibaraki,   
Japan) by using Lipofectamine 2000 (Invitrogen) according to the manufac-
turer’s instructions. After overnight incubation, the culture medium was re-
placed with a fresh one, and the cell cultures were continued for another 
36 h. Culture supernatants containing recombinant lentiviruses were then 
collected and used to transduce MCPH1 patient cells. 2 d after the transduc-
tion, cell populations resistant to G418 (at a final concentration of 250 µg/ml) 
were selected for 5 d before being subjected to the analyses of PLCs and 
chromosome spreads. For immunoblotting analysis of total lysates, 2.5 × 
10
5 cells were resuspended in 50 µl SDS sample buffer and heat denatured 
for 5 min, and a 5-µl aliquot was subjected to SDS-PAGE.
Analysis of PLCs
Cells were grown on coverslips coated with poly-l-lysine, fixed with 2% 
paraformaldehyde in PBS, pH 7.4, for 15 min, permeabilized in 0.5% Triton 
X-100 in PBS for 5 min at room temperature, and then stained with DAPI. 
The coverslips were mounted on slides with Vectashield. The cell images 
were captured with the high-throughput imaging device (CELAVIEW-RS100; 
Olympus) with LUCPlanFLN 20×/0.45 NA objective lens (Olympus). To re-
fine the analysis of PLCs, cell populations displaying nuclear GFP signals 
above a certain threshold were selected from G418-resistant cells by using 
the CELAVIEW software (Olympus). According to this strategy, 20% of to-
tal cells were judged as GFP positive in most cases. Approximately 1,000 
cells were chosen randomly from this GFP-positive population, and mitotic 
cells, except those in prophase, were removed manually. PLCs were then 
judged by DAPI stain, and its percentage was scored. The statistical signifi-
cance in mean values among multiple sample groups was examined with 
Tukey’s multiple comparison test after one-way analysis of variance test.   
Values shown in Figs. 7 (B and E) and S5 E represent the means ± SD.
Preparation of chromosome spreads
Control and transduced cells were treated with colcemid at a final con-
centration of 0.02 µg/ml for 3 h before mitotic cells were collected by 
tapping culture dishes. The collected cells were then treated with 75 mM JCB • VOLUME 194 • NUMBER 6 • 2011   854
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